Prefrontal cortex transcriptomes distinguish Alzheimer’s disease from asymptomatic amyloid pathology, neuropeptide loss, immune-complement activation and glial remodelling
This study identifies significant transcriptional changes in Alzheimer's disease, including a reduction in neuropeptide signaling, but the small sample size necessitates further research for validation.
Where it sits
this study against the rest of the vip (vasoactive intestinal polypeptide) corpusSummary and findings
This study analyzed bulk RNA-sequencing data from the dorsolateral prefrontal cortex of 15 donors to distinguish between Alzheimer's disease (AD), asymptomatic amyloid pathology, and pathology-free controls. The analysis identified 341 differentially expressed genes in AD compared to normal controls and 496 in AD compared to pathology ageing. Notably, genes related to neuropeptide signaling, including VIP, were found to be reduced in AD.
Abstract
Alzheimer’s disease (AD) is now defined biologically by cortical amyloid-β (A) and tau (T) pathology, yet the transcriptional programmes that separate symptomatic AD (A+T+) from amyloid-positive, tau-negative pathology ageing (A+T−) and from pathology-free controls (A−T−) remain incompletely resolved in the association cortex. We re-analysed bulk RNA-sequencing data from the dorsolateral prefrontal cortex (DLPFC) of 15 donors (BioProject PRJNA1017546; 87 sequencing runs aggregated to donor level): Normal (n = 2), pathology ageing (n = 5) and AD (n = 8). Differential expression was tested with DESeq2 (adjusted P < 0.05, |log fold change| > 1), and up- and down-regulated gene sets were analysed separately by Gene Ontology (GO) and KEGG over-representation. APOE and TREM2 p.Arg47His contrasts were treated as exploratory. AD versus Normal yielded 341 differentially expressed genes (DEGs; 223 up, 118 down) and AD versus pathology ageing yielded 496 (358 up, 138 down), whereas pathology ageing versus Normal yielded only six. Genes reduced in AD were dominated by neuropeptide and hormone signalling ( VGF , VIP , CRH , GRP , TAC1 , PENK ; neuroactive ligand–receptor interaction, adjusted P = 8.8 × 10; neuropeptide hormone activity, adjusted P = 6.3 × 10), most of which also differed from pathology ageing. Genes increased in AD were enriched for interferon-γ response, myeloid activation, adaptive immunity and classical complement ( C1QA , C1QB , C1QC ). Relative to pathology ageing, AD additionally showed induction of gliogenesis, oligodendrocyte differentiation and myelination programmes (gliogenesis, 21 genes, adjusted P = 2.6 × 10; SOX10 , MYRF ) and of the microglial purinergic receptor gene P2RX7 (log FC = 1.46, adjusted P = 1.5 × 10). All six pathology-ageing DEGs, including the myeloid genes VSIG4 and CD163 , were also DEGs in AD, and 50 DEGs shared by the two AD contrasts moved in the same direction. Genotype-stratified analyses were underpowered or confounded with diagnosis. In the DLPFC, AD is therefore characterised by a graded loss of neuropeptidergic signalling, myeloid–complement activation that begins at the pathology-ageing stage, and an AD-specific glial/oligodendrocyte response. These signatures nominate candidate biomarkers and mechanisms for early intervention, but the small cohort demands replication in larger, covariate-annotated datasets.
Background
This study addresses the transcriptional differences that distinguish symptomatic Alzheimer's disease (AD) from asymptomatic amyloid pathology and normal aging. Previous research has identified amyloid-β and tau pathology as key features of AD, but the specific gene expression changes associated with these conditions remain unclear. Understanding these differences is crucial for identifying potential biomarkers and therapeutic targets.
Methods
The study re-analyzed bulk RNA-sequencing data from the dorsolateral prefrontal cortex of 15 donors, categorized into normal (n=2), pathology ageing (n=5), and AD (n=8). Differential expression was assessed using DESeq2 with an adjusted P-value threshold of <0.05 and a log fold change cutoff of >1. The primary outcome measures included the number of differentially expressed genes between the groups.
Results
The primary endpoint revealed 341 differentially expressed genes in AD compared to normal controls, with 223 genes upregulated and 118 downregulated. In the comparison of AD to pathology ageing, 496 DEGs were identified, with 358 upregulated and 138 downregulated. Notably, genes associated with neuropeptide signaling, including VIP, were significantly reduced in AD, with an adjusted P-value of 6.3 × 10.
Interpretation
These findings suggest that AD is characterized by a significant loss of neuropeptidergic signaling, which is not only statistically significant but may also have clinical implications for understanding disease progression. However, the small sample size and potential confounding factors limit the robustness of these conclusions. The results align with existing literature on neuroinflammation and neuropeptide signaling in AD but require further validation in larger cohorts.
Key findings
- 341 differentially expressed genes (DEGs) in AD versus Normal, n=15, adjusted P < 0.05.
- 496 DEGs in AD versus pathology ageing, n=15, adjusted P < 0.05.
- 223 genes upregulated and 118 downregulated in AD versus Normal.
- 358 genes upregulated and 138 downregulated in AD versus pathology ageing.
- Neuropeptide and hormone signaling genes reduced in AD included VIP, adjusted P = 6.3 × 10.
Limitations
- small cohort of 15 donors
- genotype-stratified analyses underpowered or confounded with diagnosis
- single-site study limits generalizability
- no long-term follow-up data reported